A Phase 3 interventional study of Panzyga and Placebo in Chronic Lymphocytic Leukemia and Hypogammaglobulinemia, sponsored by Octapharma. Completed at 84 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Octapharma · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States — 138 open to participants now, 252 under way, 34 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · United States.
Among the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, this one is the 103rd largest by enrollment of the 1,298 interventional ones that give a count, is one of 50 that started in 2020, is one of 114 in phase 3, and was the 1,294th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →138 of the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States are open now. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
Roswell Park Cancer Institute · Sites in United States
Ages 18+
Jennifer Woyach · Sites in United States
Ages 18+
Nurix Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,501 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 657 · Phase 2 724 · Phase 3 120 · Phase 4 6
First in 1986; this study’s year is marked. 50 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 247 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 36 across the 1,298 interventional studies, 135 across the 91 observational. Of the 1,167 that completed or were terminated, 470 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
398 of 1,501 have an industry lead sponsor. The 10 most frequent:
Octapharma is the lead sponsor of 71 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 16 (94%) have results posted.
Octapharma has 1 study filed under Leukemia, Lymphocytic, Chronic, B-Cell — fewer than ten, so there is no comparison to draw.
83 of the studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT05624554Phase 3Merck Sharp & Dohme LLCA Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) | 2027-05-19 |
| NCT05057494Phase 3AstraZenecaA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 2027-07-15 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
Add all 83 to your calendar (.ics) → With an account.
Among the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Panzyga
Other: Placebo
Panzyga is a 10% IVIG produced from a pool of human fresh frozen plasma donations
Placebo
Occurrence of Major Infections
The occurrence of major infections was measured as number of participants with major infections. Major infection for this trial was defined as: * Bacterial and/or viral infections resulting in death * Bacterial and/or viral infections, which are microbiologically documented or clinically documented requiring treatment with anti-infectives; upper respiratory tract infections, bronchitis, lower urinary tract infections, localized skin infections and stomatitis are considered major only if they require treatment with antiinfectives AND hospitalization or hospitalization prolongation. * Fever of unknown origin requiring hospitalization or hospitalization prolongation
Time frame: From first treatment to the occurrence of a major infection or to the end of study visit. The median study duration of participants completing the study was 366 days. For delayed end of study visits 3 participants stayed in the study for 407 days or more.
Overall Infection Rate
Overall infection rate was measured as number of all infections per person year. Person years include participants who experienced at least one infection during the study or who completed the study without experiencing any infection.
Time frame: From first treatment to last study visit, with a median time frame of 365 days. For delayed end of study visits 3 participants stayed in the study for 407 days or more.
Frequency of Prophylaxis With Anti-infectives
Frequency of prophylaxis was defined as the number of prophylactic anti-infective medications, received per participant. Prophylactic anti-Infective medications included antibacterials and antivirals. They were defined as any medications recorded with the indication 'Infection prophylaxis' and qualifying drug code according to WHO Drug Standardised Drug Grouping 'Anti-infectives'.
Time frame: From first treatment to last study visit, with a median time frame of 365 days. For delayed end of study visits 3 participants stayed in the study for 407 days or more.
Duration of Prophylaxis With Anti-infectives
Duration of prophylaxis was defined as the sum of the number of days of the participants received prophylaxis with anti-infectives. Prophylactic anti-Infective medications included antibacterials and antivirals.
Time frame: From first treatment to last study visit, with a median time frame of 365 days. For delayed end of study visits 3 participants stayed in the study for 407 days or more.
This study was conducted at 57 study centers in 10 countries i.e., in the United States, Russia, Greece, Spain, Hungary, Italy, Czech Republic, Denmark, Poland, and Türkiye. The first participant was enrolled in October 2020 and the last participant completed the study in September 2025.
| Milestone | Panzyga | Placebo |
|---|---|---|
| Started | 124 | 123 |
| Completed | 94 | 89 |
| Not completed | 30 | 34 |
| Withdrew: Withdrawal by subject | 9 | 18 |
| Withdrew: Adverse event | 16 | 10 |
| Withdrew: Protocol violation | 4 | 4 |
| Withdrew: Lost to follow-up | 1 | 2 |
The occurrence of major infections was measured as number of participants with major infections. Major infection for this trial was defined as: * Bacterial and/or viral infections resulting in death * Bacterial and/or viral infections, which are microbiologically documented or clinically documented requiring treatment with anti-infectives; upper respiratory tract infections, bronchitis, lower urinary tract infections, localized skin infections and stomatitis are considered major only if they require treatment with antiinfectives AND hospitalization or hospitalization prolongation. * Fever of unknown origin requiring hospitalization or hospitalization prolongation
| Participants | Panzyga | Placebo |
|---|---|---|
| Occurrence of Major Infections | 14 | 27 |
Overall infection rate was measured as number of all infections per person year. Person years include participants who experienced at least one infection during the study or who completed the study without experiencing any infection.
| number of infections per person year | Panzyga | Placebo |
|---|---|---|
| Overall Infection Rate | 1.15 | 1.65 |
Frequency of prophylaxis was defined as the number of prophylactic anti-infective medications, received per participant. Prophylactic anti-Infective medications included antibacterials and antivirals. They were defined as any medications recorded with the indication 'Infection prophylaxis' and qualifying drug code according to WHO Drug Standardised Drug Grouping 'Anti-infectives'.
| number of medication per participant | Panzyga | Placebo |
|---|---|---|
| Frequency of Prophylaxis With Anti-infectives | 1.9 ± 1.26 | 1.9 ± 0.78 |
Duration of prophylaxis was defined as the sum of the number of days of the participants received prophylaxis with anti-infectives. Prophylactic anti-Infective medications included antibacterials and antivirals.
| sum of number of days | Panzyga | Placebo |
|---|---|---|
| Duration of Prophylaxis With Anti-infectives | 363.0 (3 to 380) | 363.0 (1 to 407) |
Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panzyga | 9/124 (7.3%) | 34/124 (27.4%) | 70/124 (56.5%) |
| Placebo | 7/123 (5.7%) | 43/123 (35%) | 69/123 (56.1%) |
| Event | Panzyga | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 4/124 | 9/123 |
| COVID-19 pneumoniaInfections and infestations | 5/124 | 4/123 |
| COVID-19Infections and infestations | 3/124 | 2/123 |
| Cardiac arrestCardiac disorders | 1/124 | 2/123 |
| Lower respiratory tract infectionInfections and infestations | 1/124 | 2/123 |
| InfectionInfections and infestations | 2/124 | 0/123 |
| Richter's syndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/124 | 0/123 |
| AnaemiaBlood and lymphatic system disorders | 0/124 | 1/123 |
| Autoimmune haemolytic anaemiaBlood and lymphatic system disorders | 0/124 | 1/123 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/124 | 1/123 |
| Event | Panzyga | Placebo |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 15/124 | 23/123 |
| Upper respiratory tract infectionInfections and infestations | 12/124 | 21/123 |
| COVID-19Infections and infestations | 17/124 | 19/123 |
| PyrexiaGeneral disorders | 11/124 | 6/123 |
| HypertensionVascular disorders | 11/124 | 8/123 |
| DiarrhoeaGastrointestinal disorders | 10/124 | 7/123 |
| Urinary tract infectionInfections and infestations | 4/124 | 8/123 |
| AnaemiaBlood and lymphatic system disorders | 8/124 | 5/123 |
| Infusion related reactionInjury, poisoning and procedural complications | 8/124 | 2/123 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/124 | 5/123 |
| Age, Customized(Participants) | Panzyga | Placebo | Total |
|---|---|---|---|
| <=17 years | 0 | 0 | 0 |
| between >=18 and <65 years | 44 | 48 | 92 |
| >=65 years | 80 | 75 | 155 |
| Sex: Female, Male(Participants) | Panzyga | Placebo | Total |
|---|---|---|---|
| Female | 42 | 51 | 93 |
| Male | 82 | 72 | 154 |
| Ethnicity (NIH/OMB)(Participants) | Panzyga | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 |
| Not Hispanic or Latino | 123 | 121 | 244 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Body Mass Index(kg/m^2) | Panzyga | Placebo | Total |
|---|---|---|---|
| Mean | 26.92 ± 4.492 | 26.71 ± 4.641 | 26.81 ± 4.559 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2020 to primary completion in Sep 2025, 59 months.
Results were first posted in Nov 2026, 1 year 1 month after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 59 months is above that.
Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Panzyga
Leukemia, Lymphocytic, Chronic, B-Cell →